Overview
- Peptide (CD)TINGTWEGDELGYK, corresponding to amino acid residues 11- 24 of rat P2RY2 (Accession P41232). Extracellular, C-terminus.
- Mouse brain and heart lysates, rat brain and lung lysates (1:200 – 1:1000).
Western blot analysis of mouse heart lysate (lanes 1 and 5), mouse brain lysate (lanes 2 and 6), rat brain lysate (lanes 3 and 7) and rat lung lysate (lanes 4 and 8):1-4. Anti-P2Y2 Receptor (extracellular) Antibody (#APR-102), (1:200).
5-8. Anti-P2Y2 Receptor (extracellular) Antibody, preincubated with P2Y2 Receptor (extracellular) Blocking Peptide (#BLP-PR102).
- Mouse brain sections (1:200).
- Mouse J774 macrophage cells (5 µg).
- Mouse BV-2 microglia (Jiang, P. et al. (2017) PLoS One 12, e0183114 (2017).
P2Y receptors belong to the G-protein coupled receptor superfamily. P2Y receptors mediate the actions of the extracellular nucleotides (ATP, ADP, UTP and UDP) and regulate several physiological responses, among them, cardiac function, platelet aggregation and SMC proliferation1.
The mammalian P2Y family currently includes eight functional receptors; P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and the UDP-glucose receptor, now renamed P2Y142-4.
The P2Y2 receptor is abundantly expressed in the apical membranes of several epithelial tissues including airway5. It has become a leading target for the treatment of cystic fibrosis. Activation of P2RY2 increases Cl- efflux and mucociliary clearance, effects that might relieve symptoms of cystic fibrosis. P2Y2 agonist therapy is tested in an attempt to bypass the dysfunctioning CFTR channel. Several P2Y2 receptor agonists, especially INS37217, being evaluated as possible targets for the treatment of cystic fibrosis.6
